Obiltoxaximab is a monoclonal antibody specifically designed to target and neutralize the protective antigen component of anthrax toxin, produced by Bacillus anthracis. This therapeutic agent is primarily used in the treatment and prevention of inhalational anthrax, particularly in individuals who may have been exposed to the bacterium. As a recombinant human IgG1 antibody, it exhibits high specificity and affinity for its target, facilitating the immune system's ability to combat anthrax infection. Obiltoxaximab functions by preventing the binding of the protective antigen to its receptor on host cells, thereby inhibiting the entry of the lethal factor and edema factor into the cells, which are critical for the pathogenicity of anthrax. The substance is administered via intravenous infusion and is typically used in conjunction with appropriate antibacterial therapy. Its safety profile has been evaluated in clinical studies, and it is approved for use in specific populations at risk of anthrax exposure.

Obiltoxaximab

1351337-07-9: Obiltoxaximab is a monoclonal antibody specifically designed to target and neutralize the protective antigen component of anthrax toxin, produced by Bacillus anthracis. This therapeutic agent is primarily used in the treatment and prevention of inhalational anthrax, particularly in individuals who may have been exposed to the bacterium. As a recombinant human IgG1 antibody, it exhibits high specificity and affinity for its target, facilitating the immune system's ability to combat anthrax infection. Obiltoxaximab functions by preventing the binding of the protective antigen to its receptor on host cells, thereby inhibiting the entry of the lethal factor and edema factor into the cells, which are critical for the pathogenicity of anthrax. The substance is administered via intravenous infusion and is typically used in conjunction with appropriate antibacterial therapy. Its safety profile has been evaluated in clinical studies, and it is approved for use in specific populations at risk of anthrax exposure.

<p>Monoclonal antibody targeting Bacillus anthracis anthrax</p>

<p>Obiltoxaximab is a monoclonal antibody targeting the free protective antigen (PA) of Bacillus anthracis, inhalational anthrax</p>

CAS 1351337-07-9

Obiltoxaximab

Obiltoxaximab

Ref: 3D-CLA1391

Obiltoxaximab

Ref: TM-T78290